Silo Pharma (SILO) Non Operating Interest Expenses (2018 - 2026)

Silo Pharma has disclosed Non Operating Interest Expenses across 9 years of filings, most recently posting $2865.0 for Q2 2026.

• In Q2 2026, Non Operating Interest Expenses rose 73.85% year-over-year to $2865.0; the TTM figure through Jun 2026 stood at $39826.0 (up 685.68% YoY), while the FY2025 annual figure was $37302.0, up 633.71% from the prior year.
• Non Operating Interest Expenses came in at $2865.0 for Q2 2026 at Silo Pharma, down from $3373.0 in the prior quarter.
• In the past five years, Non Operating Interest Expenses ranged from a high of $71190.0 in Q1 2022 to a low of $273.0 in Q4 2023.
• Average Non Operating Interest Expenses over 5 years is $7463.6, with a median of $1859.0 recorded in 2024.
• Year-over-year, Non Operating Interest Expenses sank 97.68% in 2023 and jumped 11835.04% in 2025.
• Over 5 years, Non Operating Interest Expenses stood at $1916.0 in 2022, then plunged by 85.75% to $273.0 in 2023, then climbed by 0.37% to $274.0 in 2024, then jumped by 11835.04% to $32702.0 in 2025, then slumped by 91.24% to $2865.0 in 2026.
• Per Business Quant data, the three most recent Non Operating Interest Expenses figures were $2865.0 in Q2 2026, $3373.0 in Q1 2026, and $32702.0 in Q4 2025.